Becton, Dickinson and’s (BDX) “Buy” Rating Reiterated at Stifel Nicolaus

Becton, Dickinson and Company (NYSE:BDX)‘s stock had its “buy” rating reissued by stock analysts at Stifel Nicolaus in a report issued on Friday. They currently have a $245.00 target price on the medical instruments supplier’s stock. Stifel Nicolaus’ price target points to a potential upside of 9.18% from the company’s previous close.

Several other research firms have also commented on BDX. Cowen and Company reaffirmed an “outperform” rating and set a $230.00 target price (up from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. BidaskClub raised Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target for the company in a research note on Monday, July 17th. Bank of America Corporation reaffirmed a “buy” rating and set a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Finally, Barclays PLC reaffirmed an “equal weight” rating and set a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Five equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Becton, Dickinson and currently has an average rating of “Buy” and an average target price of $211.94.

Shares of Becton, Dickinson and (NYSE BDX) traded up $16.35 during midday trading on Friday, reaching $224.41. The company’s stock had a trading volume of 932,032 shares, compared to its average volume of 1,325,794. The stock has a market cap of $50.98 billion, a price-to-earnings ratio of 23.61 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The firm had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. During the same quarter in the prior year, the firm posted $2.12 earnings per share. Becton, Dickinson and’s revenue for the quarter was down 2.0% compared to the same quarter last year. analysts anticipate that Becton, Dickinson and will post 10.65 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Becton, Dickinson and’s (BDX) “Buy” Rating Reiterated at Stifel Nicolaus” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/11/03/becton-dickinson-ands-bdx-buy-rating-reiterated-at-stifel-nicolaus.html.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction on Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the sale, the insider now owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the sale, the insider now directly owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. Insiders sold 75,904 shares of company stock valued at $15,242,688 in the last quarter. 1.40% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Becton, Dickinson and by 8.5% during the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after purchasing an additional 1,353,780 shares in the last quarter. BlackRock Inc. lifted its position in Becton, Dickinson and by 2,427.8% in the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after acquiring an additional 15,887,611 shares in the last quarter. State Street Corp lifted its position in Becton, Dickinson and by 3.5% in the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after acquiring an additional 342,873 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Becton, Dickinson and by 6.5% in the 1st quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after acquiring an additional 242,081 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Becton, Dickinson and by 4.0% in the 2nd quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock valued at $549,028,000 after acquiring an additional 106,966 shares in the last quarter. 86.70% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

What are top analysts saying about Becton Dickinson and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Becton Dickinson and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit